Clinical EEG and Neuroscience最新文献

{"title":"P300 Following Four Voluntarily Regulated Yoga Breathing Practices and Breath Awareness.","authors":"Niranjan Kala,&nbsp;Shirley Telles,&nbsp;Sachin Kumar Sharma,&nbsp;Acharya Balkrishna","doi":"10.1177/15500594221089369","DOIUrl":"https://doi.org/10.1177/15500594221089369","url":null,"abstract":"<p><p>Attention was influenced by yoga breathing in previously published research. Each yoga breathing practice uniquely modifies specific breath characteristics. Differences in the study designs, assessment methods and interventions resulted in difficulty in comparing effects between yoga breathing practices. This study aimed (i) to compare four yoga breathing practices on attention using an auditory oddball task and (ii) to determine cardiac autonomic activity associated with attention using heart rate variability. P300 event related potential was recorded simultaneously with heart rate variability before and after 18-minute periods each of (i) high frequency yoga breathing (with increased breath frequency), (ii) bellows yoga breathing (with increased depth of respiration), (iii) alternate nostril yoga breathing (with alternate nostril patency), (iv) bumblebee yoga breathing (with prolonged exhale), (v) breath awareness (with attention to the breath) and (vi) quiet seated rest as control in 38 yoga experienced males (average age ± <i>SD</i>; 24.08 ± 4.01 years). The six sessions were on separate, randomly allocated days. The P300 peak amplitude recorded at Pz was significantly increased after four yoga breathing practices (Bonferroni adjusted <i>post-hoc</i> tests, repeated measures ANOVA). No significant changes were noted in heart rate variability following yoga breathing or control sessions. These findings suggest that the four yoga breathing practices increase the attentional neural resources engaged for this auditory oddball task, irrespective of the characteristic of breath uniquely regulated in the four yoga breathing practices.</p>","PeriodicalId":10682,"journal":{"name":"Clinical EEG and Neuroscience","volume":"54 2","pages":"117-129"},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10671058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Class Activation Map-Based Interpretable Transfer Learning Model for Automated Detection of ADHD from fMRI Data.","authors":"Caglar Uyulan,&nbsp;Turker Tekin Erguzel,&nbsp;Omer Turk,&nbsp;Shams Farhad,&nbsp;Baris Metin,&nbsp;Nevzat Tarhan","doi":"10.1177/15500594221122699","DOIUrl":"https://doi.org/10.1177/15500594221122699","url":null,"abstract":"<p><p>Automatic detection of Attention Deficit Hyperactivity Disorder (ADHD) based on the functional Magnetic Resonance Imaging (fMRI) through Deep Learning (DL) is becoming a quite useful methodology due to the curse of-dimensionality problem of the data is solved. Also, this method proposes an invasive and robust solution to the variances in data acquisition and class distribution imbalances. In this paper, a transfer learning approach, specifically ResNet-50 type pre-trained 2D-Convolutional Neural Network (CNN) was used to automatically classify ADHD and healthy children. The results demonstrated that ResNet-50 architecture with 10-k cross-validation (CV) achieves an overall classification accuracy of 93.45%. The interpretation of the results was done via the Class Activation Map (CAM) analysis which showed that children with ADHD differed from controls in a wide range of brain areas including frontal, parietal and temporal lobes.</p>","PeriodicalId":10682,"journal":{"name":"Clinical EEG and Neuroscience","volume":"54 2","pages":"151-159"},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10494448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When to Choose Paroxetine Treatment in Skin-Picking Disorder: A Case Report.","authors":"Mehmet K Arıkan,&nbsp;Muazzez Ç Oba,&nbsp;Reyhan İlhan,&nbsp;Mehmet C Mat","doi":"10.1177/15500594211073390","DOIUrl":"https://doi.org/10.1177/15500594211073390","url":null,"abstract":"<p><p>Skin picking disorder (SPD) characterized by repetitive compulsive scratching in the absence of a primary skin disease is strongly associated with psychiatric comorbidities, including obsessive-compulsive disorder (OCD) and depression (MDD). Selective serotonin reuptake inhibitors (SSRIs) have been used in the treatment of SPD with variable success. Nevertheless, the optimum treatment choice for SPD is an issue for clinicians. This case report presents a 32-year-old female SPD patient treated with four-week paroxetine monotherapy. Based upon the clinical interview and standardized questionnaires, the patient was diagnosed with OCD with depressive features and Skin Picking Disorder. In addition to symptom severity scales, quantitative electroencephalography (qEEG) was also applied. Paroxetine treatment was started (titrated from 5 to 40 mg/day) and doubled each week. After four-week paroxetine monotherapy, OCD symptoms were diminished, and skin lesions were completely regressed leaving solely post inflammatory hyperpigmentation. Post-treatment qEEG assessment also showed a normalization of frontal alpha power and amplitude asymmetry. It can be concluded that if OCD includes SPD with abnormal EEG patterns; then the treatment success using paroxetine will be very high.</p>","PeriodicalId":10682,"journal":{"name":"Clinical EEG and Neuroscience","volume":"54 2","pages":"168-172"},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10493885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EEG - Imaging Evolution of the MV2 Subtype of Sporadic Creutzfeldt-Jakob Disease During the two-Year Course of the Disease.","authors":"Afrantou Theodora,&nbsp;Syntila Styliani-Aggeliki,&nbsp;Ioannidis Panagiotis,&nbsp;Sklaviadis Theodoros,&nbsp;Boziki Marina,&nbsp;Grigoriadis Nikolaos","doi":"10.1177/15500594221101628","DOIUrl":"https://doi.org/10.1177/15500594221101628","url":null,"abstract":"<p><p>Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare transmissible disease. According to molecular classification, six clinical phenotypes of sCJD have been described: MM1, MM2, MV1, MV2, VV1 and VV2. MV2 subtype comprises 9% of sCJD cases. Atypical clinical course has been reported to be the main caveat for the diagnosis of the MV2 subtype. We hereby present a rare case of MV2 subtype of sCJD, highlighting the evolution of clinical, EEG and imaging attributes over a two-year period, thus underlining the atypical course of the disease.</p>","PeriodicalId":10682,"journal":{"name":"Clinical EEG and Neuroscience","volume":"54 2","pages":"164-167"},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10495738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflection of the Ictal Electrocorticographic Discharges Confined to the Medial Temporal Lobe to the Scalp-Recorded Electroencephalogram.","authors":"Nobutaka Mukae,&nbsp;Takafumi Shimogawa,&nbsp;Ayumi Sakata,&nbsp;Taira Uehara,&nbsp;Hiroshi Shigeto,&nbsp;Koji Yoshimoto,&nbsp;Takato Morioka","doi":"10.1177/15500594211062702","DOIUrl":"https://doi.org/10.1177/15500594211062702","url":null,"abstract":"<p><p><b>Objective:</b> Previous reports on the simultaneous recording of electroencephalography (EEG) and electrocorticography (ECoG) have demonstrated that, in patients with temporal lobe epilepsy (TLE), ictal ECoG discharges with an amplitude as high as 1000 μV originating from the medial temporal lobe could not be recorded on EEG. In contrast, ictal EEG discharges were recorded after ictal ECoG discharges propagated to the lateral temporal lobe. Here, we report a case of TLE in which the ictal EEG discharges, corresponding to ictal ECoG discharges confined to the medial temporal lobe, were recorded. <b>Case report:</b> In the present case, ictal EEG discharges were hardly recognized when the amplitude of the ECoG discharges was less than 1500 μV. During the evolution and burst suppression phase, corresponding to highly synchronized ECoG discharges with amplitudes greater than 1500 to 2000 μV, rhythmic negative waves with the same frequency were clearly recorded both on the lateral temporal lobe and scalp. The amplitude of the lateral temporal ECoG was approximately one-tenth of that of the medial temporal ECoG. The amplitude of the scalp EEG was approximately one-tenth of that of the lateral temporal ECoG. <b>Conclusions:</b> Highly synchronized ictal ECoG discharges with high amplitude of greater than 1500 to 2000 μV in the medial temporal lobe could be recorded on the scalp as ictal EEG discharges via volume conduction.</p>","PeriodicalId":10682,"journal":{"name":"Clinical EEG and Neuroscience","volume":"54 2","pages":"173-178"},"PeriodicalIF":2.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10489033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mild Cognitive Impairment: Diagnosis and Subtypes.","authors":"Nicholas I Bradfield","doi":"10.1177/15500594211042708","DOIUrl":"https://doi.org/10.1177/15500594211042708","url":null,"abstract":"<p><p>Mild cognitive impairment (MCI) is a clinical diagnosis based on subjective cognitive decline, objective cognitive impairment, and relative preservation of activities of daily living. The diagnosis may be established via clinical interview, collateral history from an informant, and psychometric examination. Various consensus groups have proposed criteria for MCI in Alzheimer's disease (AD), Parkinson's disease, dementia with Lewy bodies, and vascular cognitive impairment. These diagnostic criteria have subtle but important differences. Criteria for subjective decline vary according to whether memory is impaired or whether impairment in any cognitive domain is sufficient. There are also differences with respect to whether the subjective decline is noted by the patient, a carer, or a clinician. The precise thresholds for classifying objective cognitive impairment also vary between various diagnostic criteria. There are also differences in the description of functional abilities. Once established, the diagnosis of MCI may be refined to 1 of 4 subtypes based on the pattern of cognitive impairment. The 4 subtypes are defined according to whether or not memory is impaired and whether 1 or more cognitive domains are impaired. Once a diagnosis of MCI has been made, the patient and the family should be counseled about social and legal implications as well as strategies for reducing the risk of progression to dementia. The main utilities of MCI as a nosology are to understand the natural history of neurodegenerative disorders such as AD, to identify those at increased risk of progressing to develop dementia, and to identifying individuals for putative treatments.</p>","PeriodicalId":10682,"journal":{"name":"Clinical EEG and Neuroscience","volume":" ","pages":"4-11"},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39438066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroimaging-Guided Transcranial Magnetic and Direct Current Stimulation in MCI: Toward an Individual, Effective and Disease-Modifying Treatment.","authors":"Lutfu Hanoglu,&nbsp;Halil Aziz Velioglu,&nbsp;Taha Hanoglu,&nbsp;Burak Yulug","doi":"10.1177/15500594211052815","DOIUrl":"https://doi.org/10.1177/15500594211052815","url":null,"abstract":"<p><p>The therapeutic approaches currently applied in Alzheimer's disease (AD) and similar neurodegenerative diseases are essentially based on pharmacological strategies. However, despite intensive research, the effectiveness of these treatments is limited to transient symptomatic effects, and they are still far from exhibiting a true therapeutic effect capable of altering prognosis. The lack of success of such pharmacotherapy-based protocols may be derived from the cases in the majority of trials being too advanced to benefit significantly in therapeutic terms at the clinical level. For neurodegenerative diseases, mild cognitive impairment (MCI) may be an early stage of the disease continuum, including Alzheimer's. Noninvasive brain stimulation (NIBS) techniques have been developed to modulate plasticity in the human cortex in the last few decades. NIBS techniques have made it possible to obtain unique findings concerning brain functions, and design novel approaches to treat various neurological and psychiatric conditions. In addition, its synaptic and cellular neurobiological effects, NIBS is an attractive treatment option in the early phases of neurodegenerative diseases, such as MCI, with its beneficial modifying effects on cellular neuroplasticity. However, there is still insufficient evidence about the potential positive clinical effects of NIBS on MCI. Furthermore, the huge variability of the clinical effects of NIBS limits its use. In this article, we reviewed the combined approach of NIBS with various neuroimaging and electrophysiological methods. Such methodologies may provide a new horizon to the path for personalized treatment, including a more individualized pathophysiology approach which might even define new specific targets for specific symptoms of neurodegenerations.</p>","PeriodicalId":10682,"journal":{"name":"Clinical EEG and Neuroscience","volume":" ","pages":"82-90"},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39602678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Special Issue: Mild Cognitive Impairment.","authors":"Norman C Moore","doi":"10.1177/15500594221132662","DOIUrl":"https://doi.org/10.1177/15500594221132662","url":null,"abstract":"Mild Cognitive Impairment (MCI) is found in Alzheimer ’ s disease (ADMCI), Parkinson ’ s disease (PDMCI), Lewy body dementia, cerebrovascular disease (Brad fi eld 1 ), sleep apnea and insomnia (Gilley 2 ). Studies have shown that monoclonal antibody treatment removes amyloid plaques from the AD brain. However, this did not result in clinical improvement in moderate and severe AD. One explanation was that the brain cells were already too damaged. Subsequent studies of mild AD and ADMCI suggested some bene fi t by reducing amyloid before the brain was too damaged. In June 2021, this led to the FDA approval of the monoclonal antibody, aducanumab, for the treatment of mild AD and ADMCI. This MCI Special Issue is timely, because the FDA approval of aducanumab has led to increased interest in ADMCI.","PeriodicalId":10682,"journal":{"name":"Clinical EEG and Neuroscience","volume":"54 1","pages":"3"},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10705818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardization and Validation of the Flash Visual Evoked Potential-P2 Conversion Scores in the Diagnosis of Amnestic Mild Cognitive Impairment and Alzheimer's Dementia.","authors":"James E Arruda,&nbsp;Madison C McInnis,&nbsp;Jessica Steele","doi":"10.1177/15500594211069727","DOIUrl":"https://doi.org/10.1177/15500594211069727","url":null,"abstract":"<p><p>Amnestic mild cognitive impairment (aMCI), which is characterized by normal daily activity, but a significant decline in episodic memory, is now widely accepted as a risk factor for the development of Alzheimer's dementia (AD). Research suggests that many of the same neuropathological changes associated with AD also occur in patients diagnosed with aMCI. A recent review of the literature revealed that the latency of the flash visual-evoked potential-P2 (FVEP-P2) may possess pathognomonic information that may assist in the early detection of aMCI. While standards exist for the recording of FVEP-P2, individual clinics often use recording parameters that may differ, resulting in latencies that may not generalize beyond the clinic that produced them. The present article illustrates the process by which the FVEP-P2 latency can be standardized across clinics using <i>FVEP-P2 Conversion Scores.</i> We then demonstrate the diagnostic accuracy of the newly developed scores. <b>Method:</b> In the present investigation, we used the previously unpublished data containing the FVEP-P2 latencies of 45 AD and 60 controls. <b>Result:</b> We were able to demonstrate the process by which individual clinics may first standardize FVEP-P2 latencies and then examine patient performance using <i>FVEP-P2 Conversion Scores</i>, providing clinicians with a richer context from which to examine the patient performance. <b>Conclusion:</b> Consistent with the findings of previous research, the findings of the present investigation support the use of the <i>FVEP-P2 Conversion Scores</i> in the diagnosis of AD. Future directions, including the modification of recording parameters associated with the FVEP-P2, are also discussed.</p>","PeriodicalId":10682,"journal":{"name":"Clinical EEG and Neuroscience","volume":" ","pages":"61-72"},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39654116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What a Single Electroencephalographic (EEG) Channel Can Tell us About Alzheimer's Disease Patients With Mild Cognitive Impairment.","authors":"Claudio Del Percio,&nbsp;Susanna Lopez,&nbsp;Giuseppe Noce,&nbsp;Roberta Lizio,&nbsp;Federico Tucci,&nbsp;Andrea Soricelli,&nbsp;Raffaele Ferri,&nbsp;Flavio Nobili,&nbsp;Dario Arnaldi,&nbsp;Francesco Famà,&nbsp;Carla Buttinelli,&nbsp;Franco Giubilei,&nbsp;Moira Marizzoni,&nbsp;Bahar Güntekin,&nbsp;Görsev Yener,&nbsp;Fabrizio Stocchi,&nbsp;Laura Vacca,&nbsp;Giovanni B Frisoni,&nbsp;Claudio Babiloni","doi":"10.1177/15500594221125033","DOIUrl":"https://doi.org/10.1177/15500594221125033","url":null,"abstract":"<p><p>Abnormalities in cortical sources of resting-state eyes closed electroencephalographic (rsEEG) rhythms recorded by hospital settings (10-20 montage) with 19 scalp electrodes characterized Alzheimer's disease (AD) from preclinical to dementia stages. An intriguing rsEEG application is the monitoring and evaluation of AD progression in large populations with few electrodes in low-cost devices. Here we evaluated whether the above-mentioned abnormalities can be observed from fewer scalp electrodes in patients with mild cognitive impairment due to AD (ADMCI). Clinical and rsEEG data acquired in hospital settings (10-20 montage) from 75 ADMCI participants and 70 age-, education-, and sex-matched normal elderly controls (Nold) were available in an Italian-Turkish archive (PDWAVES Consortium; www.pdwaves.eu). Standard spectral fast fourier transform (FFT) analysis of rsEEG data for individual delta, theta, and alpha frequency bands was computed from 6 monopolar scalp electrodes to derive bipolar C3-P3, C4-P4, P3-O1, and P4-O2 markers. The ADMCI group showed increased delta and decreased alpha power density at the C3-P3, C4-P4, P3-O1, and P4-O2 bipolar channels compared to the Nold group. Increased theta power density for ADMCI patients was observed only at the C3-P3 bipolar channel. Best classification accuracy between the ADMCI and Nold individuals reached 81% (area under the receiver operating characteristic curve) using Alpha2/Theta power density computed at the C3-P3 bipolar channel. Standard rsEEG power density computed from six posterior bipolar channels characterized ADMCI status. These results may pave the way toward diffuse clinical applications in health monitoring of dementia using low-cost EEG systems with a strict number of electrodes in lower- and middle-income countries.</p>","PeriodicalId":10682,"journal":{"name":"Clinical EEG and Neuroscience","volume":" ","pages":"21-35"},"PeriodicalIF":2.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40700355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}